The year's biggest meeting of cancer researchers was subjected to a coronavirus overhaul this year, but even in scaled-back form it forced investors to recalibrate their expectations for some closely watched medicines.
Jun 02, 2020
0
0
Highly focused, intense doses of radiation called stereotactic ablative radiation (SABR) may slow progression of disease in a subset of men with hormone-sensitive prostate cancers that have spread to a few separate sites ...
Mar 26, 2020
0
41
For most patients, melanoma begins with a small, pigmented spot on their skin that they notice starts to change. Many primary melanomas can be cured by having this lesion removed, but melanoma can also recur and spread; an ...
Jan 20, 2020
0
110
(HealthDay)—Young, low-income patients with bone or soft tissue sarcomas have decreased overall survival (OS), regardless of disease stage at presentation, according to a study published online Dec. 15 in Cancer Medicine.
Dec 27, 2019
0
3
A Mayo Clinic study involving 5,540 patients with metastatic colorectal cancer finds that maintenance chemotherapy after initial treatment is more beneficial for patients whose disease is under control, compared with more ...
Dec 19, 2019
0
17
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with ...
Sep 30, 2019
0
15
New prostate cancer research shows that adding an interim scan during therapy can help guide a patient's treatment. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging of patients with metastatic ...
Jun 24, 2019
0
0
(HealthDay)—Piqray (alpelisib) tablets were approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in ...
May 28, 2019
0
1
For about 90 percent of men with prostate cancer, the cancer remains localized to the primary site, resulting in a five-year survival rate of almost 100 percent. Unfortunately, the remaining 10 percent of patients develop ...
May 09, 2019
0
84
Some patients with metastatic prostate cancer respond to a combination of immune checkpoint inhibitors after hormonal therapy and chemotherapy have failed, according to early results from a clinical trial led by investigators ...
Feb 15, 2019
0
2
